Successfully utilized contemporary pulmonary embolism thrombolysis reverses right heart failure rapidly and safely. This therapeutic approach may lower mortality from pulmonary embolism and reduce morbidity from chronic pulmonary hypertension. Unlike myocardial infarction thrombolysis, a 2-week 'time window' is available, during which treatment can be initiated. A high concentration of the thrombolytic agent is administered in a brief infusion lasting several hours. No special laboratory testing is needed. Currently, the only contemporary thrombolytic regimen for pulmonary embolism that is approved by the Food and Drug Administration is tissue plasminogen activator, in a dose of 100 mg/2 h. New thrombolytic agents under development for pulmonary embolism include reteplase, saruplase, and recombinant staphylokinase. Future clinical trials will require multicenter collaboration and will focus on relevant endpoints such as the reduction of mortality and recurrent venous thromboembolism.
Introduction
Pulmonary embolism (PE) is a common cardiopulmonary illness that can cause right ventricular failure, chronic pulmonary hypertension, and death. At the beginning of this new millennium, the mortality rate among PE patients remains surprisingly high: in the order of 15% in an unselected prospective registry of patients. 1 Acute right heart failure from PE can cause dyspnea, peripheral edema, and cardiogenic shock. Death may ensue owing to right ventricular dilatation, compression of the left ventricle by the interventricular septum, and decreased forward cardiac output.
For patients with massive PE and cardiogenic shock, thrombolysis can be life-saving. 2 In a small clinical trial, patients with hypotension and heart failure owing to PE were randomized to thrombolysis (streptokinase 1 500 000 U/h) plus anticoagulation versus anticoagulation alone. The trial was stopped after the first eight of a planned 40 patients were enrolled because all four patients allocated to the anticoagulation alone group died; in contrast, all four patients who received thrombolysis survived. Of the four patients who died, three underwent post mortem examination and were revealed to have had right ventricular myocardial infarction (without significant coronary arterial obstruction) in addition to massive PE. Thus, these results support what appears to be intuitively apparent: thrombolysis can help avert death from progressive right heart failure among PE patients in cardiogenic shock.
Consensus exists that thrombolysis or embolectomy should be utilized for massive PE, which occurs rarely.
Consensus is lacking, however, on the much more commonly encountered clinical dilemma: whether thrombolysis should be administered to PE patients with impending hemodynamic instability -those with right ventricular dysfunction on an echocardiogram but preserved systemic arterial pressure. 3 In the International Cooperative Pulmonary Embolism Registry (ICOPER) of 2454 patients, fewer than 5% presented in cardiogenic shock. 1 Among the half who underwent baseline echocardiography, right ventricular hypokinesis was detected in 40%. Multivariate analysis indicated that right ventricular hypokinesis was independently associated with a doubling of the 3-month mortality rate. Similar observations were made in registries from Germany 4 and Sweden. 5
Pathophysiology
The hemodynamic response to PE depends upon the size of the embolus, coexistent cardiopulmonary disease, and neurohumoral effects. Pulmonary artery obstruction and circulating neurohumoral substances reduce the pulmonary vascular bed and cause an increase in right ventricular afterload. As right ventricular and pulmonary artery pressures rise, the right ventricle dilates, becomes hypokinetic, and ultimately fails. Acute increases in right ventricular pressure can cause left ventricular dysfunction because of the anatomical juxtaposition of the two ventricles and 'ventricular interdependency.' Moderate right ventricular hypertension can displace the interventricular septum toward the left ventricle, resulting in decreased left ventricular diastolic filling and end-diastolic volume, as well as right ventricular ischemia, infarction, and circulatory collapse ( Figure 1 ). 6 With underfilling of the left ventricle, systemic cardiac output and pressure both decrease, potentially compromising coronary perfusion and producing myocardial ischemia. By relieving obstruction to pulmonary artery blood flow, thrombolysis can rapidly lower the abnormally elevated pulmonary artery pressure, thereby reversing cardiogenic shock and possibly reducing the mortality rate from PE.
Prognosis with heparin alone
Among patients treated with heparin alone, the rate of death or recurrent PE within 2 weeks of diagnosis was 10% in the cohort of 399 patients followed by the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED) group. 7 Only 6% of the 399 PE patients received thrombolytic therapy. When 1-year mortality rates from all causes were assessed, patients who had received anticoagulation alone had a 19% mortality rate. In contrast, the lowest allcause mortality rate was 9% in the group treated with thrombolytic therapy.
In the much larger Management Strategy And Prognosis of Pulmonary Embolism Registry (MAPPET), 1001 patients with right ventricular dysfunction were enrolled. 8 Initial use of thrombolytic therapy among a subset of the 719 who presented with a normal systemic arterial pressure was associated with reduced in-hospital mortality and recurrent PE (Table 1 ). 9 After multivariate analysis, a marked benefit persisted for the thrombolysis-treated patients. Despite its limitations, MAPPET provides additional support for the hypothesis that thrombolysis will benefit PE patients who present with the combination of normal systemic arterial pressure and right ventricular dysfunction. 
Initial clinical trials
Urokinase (UK) was compared with heparin alone in 160 patients with angiographically documented PE who participated in Phase I of the Urokinase Pulmonary Embolism Trial (UPET). 10 The urokinase-dosing regimen was 4400 U/kg as a loading dose followed by 4400 U/kg per hour for 24 h. Urokinase dissolved pulmonary arterial clot more rapidly than heparin alone and, in certain instances, reversed clinical shock. However, there was no difference in the rate of death or recurrent PE between the two groups ( Table 2 ). Furthermore, hemorrhagic complications occurred more often among those patients randomized to urokinase ( Table 3 ).
In the Urokinase-Streptokinase PE Trial (USPET), 11 167 patients with angiographically documented PE were randomized to one of three different thrombolytic treatments: 12 h of urokinase, 24 h of urokinase, or 24 h of streptokin- ase. When the three thrombolytic regimens were compared, morbidity and mortality were similar (Table 4 ) as was the frequency of major bleeding complications ( Table 5 ). In a small ancillary study, acute thrombolysis followed by heparin improved pulmonary capillary blood volume at 2 weeks and at 1 year more than heparin alone. 12 When followed for an average of 7 years, those assigned initially to thrombolysis appeared to have a more complete resolution of PE, as assessed by preservation of the normal pulmonary vascular response to exercise. 13
Contemporary clinical trials
PAIMS-2 investigators in Italy 14 randomized 36 patients with angiographically proven PE to 100 mg of recombinant human tissue-type plasminogen activator (rt-PA) over 2 h or to heparin. Clot lysis at follow-up angiography occurred in the rt-PA group but not among heparin alone patients. Mean pulmonary artery pressure decreased from 30 mmHg to 21 mmHg in the rt-PA group, but increased in patients who received heparin alone. Two rt-PA patients died (one from renal failure following cardiac tamponade and one from intracranial bleeding), and one patient who received heparin alone died from recurrent PE. European Cooperative Study Group Investigators compared 100 mg of rt-PA over 2 h with a 12-h weight-adjusted infusion of UK (4400 U/kg bolus, followed by 4400 U/kg per hour for 12 h). 15 The principal endpoint was a reduction in total pulmonary resistance, defined as pulmonary artery mean pressure divided by cardiac index. At 2 h, total pulmonary resistance decreased by 36% in the rt-PA group, compared with an 18% decrease in UK-treated patients (p = 0.0009). However, by 6 h, UK appeared to 'catch up' to rt-PA, and hemodynamic differences between the two groups did not persist.
Goldhaber's PE Trial #3 compressed the 24-h dose of urokinase to make it more comparable with the high concentration/short infusion period that was used for rt-PA. 16 The novel UK dose was 3 000 000 U/2 h, with the first 1 000 000 U given as a bolus over 10 min ( Figure 2 ). This trial enrolled 90 patients. Repeat pulmonary angiograms at 2 h were performed in 87 patients and then graded by a blinded panel ( Figure 3 ). Overall, 67% of UK patients showed angiographic improvement compared with 79% of rt-PA patients. Virtually no patient in the trial experienced complete resolution of thrombus. Baseline and 24-h followup perfusion lung scans were also obtained ( Figure 4 ). The results indicated that a 2-h regimen of rt-PA and a new concentrated 2-h dosing regimen of UK exhibit similar efficacy and safety for treatment of acute pulmonary embolism.
Goldhaber's PE Trial #4 tested the hypothesis that rt-PA followed by anticoagulation accelerates the improvement of right ventricular function and pulmonary perfusion more and pulmonary perfusion among patients with PE and may lead to a lower rate of adverse clinical outcomes. In this multicenter randomized controlled trial, 101 patients were randomized: 46 to rt-PA 100 mg/2 h followed by heparin and 55 to heparin alone. 17 Thus, PE Trial #4 is the largest thrombolysis versus heparin trial that has been undertaken since Phase I of the Urokinase Pulmonary Embolism Trial. 10 PE Trial #4 tested the efficacy of thrombolytic therapy among a population of 'hemodynamically stable' patients. No patient presented with an initial systolic arterial pressure less than 90 mmHg. Only 20% of the patients underwent diagnostic pulmonary angiograms. The others were enrolled on the basis of high probability lung scans.
At baseline, slightly more than half of the patients with PE had entirely normal right ventricular function. Qualitative assessment of right ventricular wall motion at baseline versus 24 h demonstrated that 39% of the rt-PA patients improved and 2.4% worsened, compared with 17% improvement and 17% worsening among those who received heparin alone (p = 0.005). Quantitative assessment showed that rt-PA patients had a significant decrease in the right ventricular end diastolic area during the 24 h after randomization compared with none among those allocated to heparin alone (p = 0.01). Decreased right ventricular dilatation indicates improved right ventricular function. The rt-PA patients also had an absolute improvement in pulmonary perfusion of 14.6% at 24 h compared with 1.5% improvement among heparin alone patients (p Ͻ 0.0001).
Most importantly, no clinical episodes of recurrent PE occurred among rt-PA patients, but there were five (two fatal and three non-fatal) clinically suspected recurrent PEs within 14 days in patients randomized to heparin alone (p = 0.06). All five presented initially with right ventricular hypokinesis as revealed by an echocardiogram, despite normal systemic arterial pressure at baseline. Thus, echocardiography helps to identify a subgroup of PE patients with impending right ventricular failure who appear to be at high risk of adverse clinical outcomes if treated with heparin alone. Such patients, in particular, may be excellent candidates for thrombolytic therapy in the absence of contraindications.
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The results from this clinical trial have modified our definition of 'hemodynamic stability.' Our findings suggest that primary therapy (as opposed to secondary prevention with anticoagulation alone) should be considered for patients with 'impending hemodynamic instability,' defined as normal systemic arterial pressure plus moderate or marked right ventricular dysfunction on echocardiogram. Because right ventricular dysfunction on echocardiography may portend clinical deterioration, we do not allow the presence of normal systemic arterial pressure to dissuade us from implementing primary thrombolytic therapy of PE.
Recently, Solomon's group showed quantitatively that most patients who receive thrombolytic therapy for PE achieve recovery of regional as well as global right ventricular function. 18
Bleeding complications
Catastrophic bleeding complications can occur with thrombolytic therapy. Therefore, all patients being considered for any thrombolytic regimen should be subjected to a meticulous evaluation for possible contraindications such as intracranial disease, recent surgery, or trauma.
With respect to thrombolysis, the most feared complication is intracranial hemorrhage. Based on our series of 312 patients receiving thrombolysis for PE in five clinical trials, there is a 1.9% risk (95% CI, 0.7-4.1%) of intracranial bleeding. 19 Six patients suffered intracranial hemorrhage; two of the six patients received thrombolysis in violation of the protocol because they had pre-existing known intracranial disease. Two of the six intracranial hemorrhages probably were due to administration of hep- arin and not thrombolysis because they occurred late, 62 h and 157 h after thrombolysis. Diastolic blood pressure on admission was significantly elevated in patients who developed intracranial hemorrhage compared with those who did not (90.3 versus 77.6 mmHg; p = 0.04). No patient under the age of 55 years was affected. These data indicate that meticulous patient screening before administering thrombolysis is imperative.
Non-invasive diagnosis
With the combination of a high clinical suspicion for PE and a high probability ventilation-perfusion lung scan, the likelihood of PE at angiography exceeds 90%. 20 Among these patients, thrombolytic therapy can be administered without angiographic confirmation of the diagnosis. Employing thrombolysis when PE is diagnosed non-invasively rather than with angiography decreases the rate of bleeding complications, particularly groin hematomas, that would otherwise occur. 21 Such a strategy also reduces the time delay until treatment and reduces cost.
Predictors of efficacy
The appearance of the initial lung scan can help predict whether thrombolysis will be successful. 22 Improvement in pulmonary perfusion after thrombolysis has been correlated with large initial perfusion defects that have a segmental appearance. These characteristics typically occur in patients who have anatomically extensive PE as well as a relatively short duration of symptoms.
There appears to be an inverse association between duration of symptoms and improvement on lung scan reperfusion after thrombolysis. 23 We observed 1.1% less reperfusion on lung scanning per additional day of symptoms (95% CI, 0.3-1.8%, p = 0.004). After controlling for age and initial lung scan defect size, there was 0.7% less reperfusion per additional day of symptoms (95% CI, 0.2-1.2%, p = 0.007). Less clot lysis on angiography immediately following thrombolysis was observed in the quintile of patients with the longest duration of symptoms (у6 days, p = 0.03). Thus, when considering administration of thrombolysis, keep in mind that delay will attenuate efficacy. Nevertheless, thrombolysis is still useful in patients who have had symptoms for 6-14 days.
Predictors of bleeding
The mean age of patients with major bleeding was 63 years, while that of patients with no hemorrhagic complication was 56 years (p = 0.005). There was a 4% increased risk of bleeding for each additional year of age. Increasing body mass index and pulmonary angiography were also significant predictors of hemorrhage. 24
PE thrombolysis in women
Data from 312 patients (144 women and 168 men) included in Goldhaber's PE Trials #1-#5 16, 17, [25] [26] [27] were analyzed to determine whether there were gender differences in the efficacy or safety of thrombolytic therapy. 28 Our results indicated that women and men have a similar benefit and bleeding risk from PE thrombolysis. These findings suggest that thrombolytic therapy should be considered in the management of PE without regard to gender.
Figure 4
This is the baseline and follow-up lung scan 24 h after urokinase administration in the same patient whose angiogram is shown in Figure 3 . The 24-h scan shows virtually normal pulmonary perfusion.
PE thrombolysis in cancer patients
Although the initial angiographic response to thrombolysis is similar in cancer and non-cancer patients, the magnitude of improvement among cancer patients becomes attenuated on perfusion scanning at 24 h. This observation suggests that cancer patients should receive maximally intensive anticoagulation immediately following thrombolysis in order to preserve their initial improvement from therapy. Fortunately, PE thrombolysis does not appear to be any more hazardous in appropriately selected cancer patients than in patients without cancer. 29
Practical points
The US Food and Drug Administration approved streptokinase (SK) in 1977 and UK in 1978 for the treatment of pulmonary embolism; rt-PA received approval in 1990. All three regimens (Table 6 ) utilize fixed or weight-adjusted doses of thrombolytic agents. Therefore, there is no need to obtain laboratory tests during the thrombolytic infusion because no dosage adjustments are made. Local administration of rt-PA within the pulmonary artery appears to confer no advantage over peripheral administration of the drug. 30 None of the FDA-approved regimens for PE thrombolysis employs concomitant heparin, an important difference when compared with thrombolysis for myocardial infarction. At the conclusion of the thrombolytic infusion, Vascular Medicine 2000; 5: 115-123 a partial thromboplastin time (PTT) should be obtained. As long as the test result is less than twice the upper limit of normal, heparin can be initiated (or resumed) as a continuous intravenous infusion, without a loading dose. Occasionally, after termination of the thrombolytic infusion, the PTT will exceed twice the upper limit of normal. In these circumstances, the test should be repeated every 4 h until it declines into the range in which heparin administration is safe.
Management of bleeding complications
If intracranial bleeding is suspected, thrombolytic therapy or heparin should be discontinued immediately, and both neurological and neurosurgical consultation should be obtained. Retroperitoneal hemorrhage can also be lifethreatening because the bleeding is often sustained, brisk, and difficult to diagnose. This complication can occur during the femoral vein catheterization for pulmonary angiography if an artery is inadvertently punctured above the inguinal ligament.
If bleeding is brisk or potentially life-threatening, 10 units of cryoprecipitate should be ordered from the blood bank. Each unit contains 200-500 mg of fibrinogen and 80 units of Factor VIII in a volume of 10-15 ml. A dose of 10 units will increase the fibrinogen level by about 70 mg/dl and the Factor VIII level by about 30% of normally circulating levels. Cryoprecipitate can be thawed rapidly and should be available within 10 min of a request. In addition, 2 units of fresh frozen plasma (FFP) should be ordered. FFP, which may take 45 min to thaw, is a source of Factors V and VIII as well as alpha-2-antiplasmin, fibrinogen, and other active coagulation factors. 31 Gross hematuria and other internal bleeding can generally be well managed by discontinuing therapy. Trivial superficial oozing at venipuncture or arterial catheter insertion sites can be controlled with manual compression followed by a pressure dressing.
Allergic reactions owing to SK or, less often, UK occur occasionally and are manifested by fever and chills. In an attempt to suppress this reaction, intravenous steroids, diphenhydramine, or oral acetaminophen can be administered prophylactically. It seems that acetaminophen 1500 mg by mouth is particularly effective. If rigors do occur, they can be treated effectively with 50-100 mg of intravenous meperidine.
Contemporary PE thrombolysis
Contemporary PE thrombolysis 32 is safer, more streamlined, and more economical than classic PE thrombolysis (Table 7) . Contemporary PE thrombolysis is characterized by a 2-week 'time window,' a brief infusion administered through a peripheral vein, and no special laboratory tests. New thrombolytic agents such as saruplase, 33 reteplase, 34 and recombinant staphylokinase 35 appear promising in small case series of PE. Future trials will require multicenter collaboration and must focus on relevant clinical endpoints such as reduction of mortality, recurrent PE, and chronic pulmonary hypertension. In the meantime, increasing evidence indicates that we should broaden the paradigm for using thrombolysis in PE. 36 
